Movement Alert｜AstraZeneca PLC Intraday Rise 3.08% in Regular Trading, US launch of Zegfrovy and FDA approval for Ultomiris supported shares

On October 23, AstraZeneca PLC rose 3.08% in Regular Trading, trading at $173.78, with turnover of $240 million.

The move followed two recent company updates: AstraZeneca PLC reported US availability of Zegfrovy for adults with locally advanced or metastatic non-small cell lung cancer with specific EGFR-related tumors, while Alexion unit drug Ultomiris received FDA accelerated approval to reduce proteinuria in adults with primary IgA nephropathy at risk of disease progression.

According to the company disclosures, Ultomiris was approved based on a prespecified interim analysis from the phase 3 I CAN trial, where it reduced proteinuria by 43.4% versus placebo at 34 weeks. The ongoing study will continue to evaluate kidney function at week 106 to support potential traditional approval. The back-to-back regulatory and commercialization milestones appear to have reinforced market expectations for AstraZeneca PLC's oncology and rare disease pipeline execution.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)